Nicotinic Receptors in Brain Diseases 775 Gahring LC, Meyer EL, Rogers SW (2003) Nicotine-induced neuroprotection against N-methyl- D-aspartic acid or beta-amyloid peptide occur through independent mechanisms distinguished by pro-inflammatory cytokines. J Neurochem 87:1125–1136 Giniatullin R, Nistri A, Yakel JL (2005) Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci 28:371–378 Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Longhi R, Riganti L, Gaimarri A, McKeith IG, Perry RH, Aarsland D, Larsen JP, Sher E, Beattie R, Clementi F, Court JA (2006a) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer’s disease, Parkinson’s disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 23: 481–489 Gotti C, Zoli M, Clementi F (2006b) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27:482–491 Grady SR, Meinerz NM, Cao J, Reynolds AM, Picciotto MR, Changeux JP, McIntosh JM, Marks MJ, Collins AC (2001) Nicotinic agonists stimulate acetylcholine release from mouse interpe- duncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J Neurochem 76:258–268 Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, Clementi F, Gotti C (2009) Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4 ∗ and alpha3beta3beta4 ∗ subtypes mediate acetylcholine release. J Neurosci 29:2272–2282 Grassi F, Palma E, Tonini R, Amici M, Ballivet M, Eusebi F (2003) Amyloid beta(1-42) pep- tide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors. J Physiol 547:147–157 Grucza RA, Wang JC, Stitzel JA, Hinrichs AL, Saccone SF, Saccone NL, Bucholz KK, Cloninger CR, Neuman RJ, Budde JP, Fox L, Bertelsen S, Kramer J, Hesselbrock V, Tischfield J, Nurnberger JI Jr, Almasy L, Porjesz B, Kuperman S, Schuckit MA, Edenberg HJ, Rice JP, Goate AM, Bierut LJ (2008) A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence. Biol Psychiatry 64:922–929 Guan ZZ, Nordberg A, Mousavi M, Rinne JO, Hellstrom-Lindahl E (2002) Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson’s disease. Brain Res 956:358–366 Guan ZZ, Zhang X, Blennow K, Nordberg A (1999) Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10: 1779–1782 Guan ZZ, Zhang X, Ravid R, Nordberg A (2000) Decreased protein levels of nicotinic recep- tor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease. J Neurochem 74:237–243 Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, Zerbe G, Freedman R (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29:1378–1385 Hellstrom-Lindahl E, Mousavi M, Ravid R, Nordberg A (2004) Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer’s patients. Neurobiol Dis 15:351–360 Hellstrom-Lindahl E, Mousavi M, Zhang X, Ravid R, Nordberg A (1999) Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Res Mol Brain Res 66:94–103 Hirose S, Iwata H, Akiyoshi H, Kobayashi K, Ito M, Wada K, Kaneko S, Mitsudome A (1999) A novel mutation of CHRNA4 responsible for autosomal dominant nocturnal frontal lobe epilepsy. Neurology 53:1749–1753 Hoda JC, Gu W, Friedli M, Phillips HA, Bertrand S, Antonarakis SE, Goudie D, Roberts R, Scheffer IE, Marini C, Patel J, Berkovic SF, Mulley JC, Steinlein OK, Bertrand D (2008) Human nocturnal frontal lobe epilepsy: pharmocogenomic profiles of pathogenic nicotinic acetylcholine receptor beta-subunit mutations outside the ion channel pore. Mol Pharmacol 74:379–391 776 J.A. Stitzel Hoda JC, Wanischeck M, Bertrand D, Steinlein OK (2009) Pleiotropic functional effects of the first epilepsy-associated mutation in the human CHRNA2 gene. FEBS Lett 583(10):1599–1604 Hogg RC, Bertrand D (2004) Nicotinic acetylcholine receptors as drug targets. Curr Drug Targets CNS Neurol Disord 3:123–130 Holzman PS (2000) Eye movements and the search for the essence of schizophrenia. Brain Res Brain Res Rev 31:350–356 Howson AL, Batth S, Ilivitsky V, Boisjoli A, Jaworski M, Mahoney C, Knott VJ (2004) Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome. Eur Psychiatry 19:102–112 Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA (1986) Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 143:993–997 Hulihan-Giblin BA, Lumpkin MD, Kellar KJ (1990) Effects of chronic administration of nico- tine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine. J Pharmacol Exp Ther 252:21–25 Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia- Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel- Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martinez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcatova I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452:633–637 Jones EL, Hanney M, Francis PT, Ballard CG (2009) Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett 451:162–164 Jones IW, Westmacott A, Chan E, Jones RW, Dineley K, O’Neill MJ, Wonnacott S (2006) Alpha7 nicotinic acetylcholine receptor expression in Alzheimer’s disease: receptor densities in brain regions of the APP(SWE) mouse model and in human peripheral blood lymphocytes. J Mol Neurosci 30:83–84 Jones IW, Wonnacott S (2005) Why doesn’t nicotinic ACh receptor immunoreactivity knock out? Trends Neurosci 28:343–345 Joslyn G, Brush G, Robertson M, Smith TL, Kalmijn J, Schuckit M, White RL (2008) Chromosome 15q25.1 genetic markers associated with level of response to alcohol in humans. Proc Natl Acad Sci U S A 105:20368–20373 Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A (2006) PET imaging of cortical 11C- nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology (Berl) 188:509–520 Kelley MP, Bakan P (1999) Eye tracking in normals: spem asymmetries and association with schizotypy. Int J Neurosci 98:27–81 Kihara T, Shimohama S, Akaike A (1999) Effects of nicotinic receptor agonists on beta-amyloid beta-sheet formation. Jpn J Pharmacol 79:393–396 Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276:13541–13546 Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A (1998) Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 792:331–334 Klaassen A, Glykys J, Maguire J, Labarca C, Mody I, Boulter J (2006) Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy. Proc Natl Acad Sci U S A 10350:19152–19157 Klink R, de Kerchove dA, Zoli M, Changeux JP (2001) Molecular and physiological diver- sity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21: 1452–1463 Nicotinic Receptors in Brain Diseases 777 Kulak JM, Musachio JL, McIntosh JM, Quik M (2002) Declines in different beta2 ∗ nicotinic receptor populations in monkey striatum after nigrostriatal damage. J Pharmacol Exp Ther 303:633–639 Labarca C, Schwarz J, Deshpande P, Schwarz S, Nowak MW, Fonck C, Nashmi R, Kofuji P, Dang H, Shi W, Fidan M, Khakh BS, Chen Z, Bowers BJ, Boulter J, Wehner JM, Lester HA (2001) Point mutant mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci U S A 98:2786–2791 Lamb PW, Melton MA, Yakel JL (2005) Inhibition of neuronal nicotinic acetylcholine recep- tor channels expressed in Xenopus oocytes by beta-amyloid1-42 peptide. J Mol Neurosci 27: 13–21 Lange KW, Wells FR, Jenner P, Marsden CD (1993) Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson’s disease. J Neurochem 60: 197–203 Le ML, Derby KS, Murphy SE, Hecht SS, Hatsukami D, Carmella SG, Tiirikainen M, Wang H (2008) Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res 68: 9137–9140 Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, Iversen P, Bauman M, Perry E (2002) Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 125:1483–1495 Lee KH, Williams LM (2000) Eye movement dysfunction as a biological marker of risk for schizophrenia. Aust N Z J Psychiatry 34(Suppl):S91–S100 Leniger T, Kananura C, Hufnagel A, Bertrand S, Bertrand D, Steinlein OK (2003) A new Chrna4 mutation with low penetrance in nocturnal frontal lobe epilepsy. Epilepsia 44:981–985 Lippiello PM (2006) Nicotinic cholinergic antagonists: a novel approach for the treatment of autism. Med Hypotheses 66:985–990 Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29:918–929 Liu Q, Kawai H, Berg DK (2001) beta -Amyloid peptide blocks the response of alpha 7- containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A 98: 4734–4739 Liu Z, Neff RA, Berg DK (2006) Sequential interplay of nicotinic and GABAergic signaling guides neuronal development. Science 314:1610–1613 Liu P, Vikis HG, Wang D, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P, de AM, Petersen GM, Wiest JS, Fain PR, Gazdar A, Gaba C, Rothschild H, Mandal D, Coons T, Lee J, Kupert E, Seminara D, Minna J, Bailey-Wilson JE, Wu X, Spitz MR, Eisen T, Houlston RS, Amos CI, Anderson MW, You M (2008) Familial aggregation of common sequence variants on 15q24- 25.1 in lung cancer. J Natl Cancer Inst 100:1326–1330 Liu Q, Zhao B (2004) Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br J Pharmacol 141:746–754 Lohr JB, Flynn K (1992) Smoking and schizophrenia. Schizophr Res 8:93–102 Lu Y, Grady S, Marks MJ, Picciotto M, Changeux JP, Collins AC (1998) Pharmacological char- acterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. J Pharmacol Exp Ther 287:648–657 Magdesian MH, Nery AA, Martins AH, Juliano MA, Juliano L, Ulrich H, Ferreira ST (2005) Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta. J Biol Chem 280:31085–31090 Mansvelder HD, Keath JR, McGehee DS (2002) Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33:905–919 Mansvelder HD, McGehee DS (2000) Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27:349–357 Marks MJ, Burch JB, Collins AC (1983) Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 226:817–825 778 J.A. Stitzel Marks MJ, Collins AC (1982) Characterization of nicotine binding in mouse brain and compar- ison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate. Mol Pharmacol 22: 554–564 Marks MJ, Rowell PP, Cao JZ, Grady SR, McCallum SE, Collins AC (2004) Subsets of acetylcholine-stimulated 86Rb+ efflux and [125I]-epibatidine binding sites in C57BL/6 mouse brain are differentially affected by chronic nicotine treatment. Neuropharmacology 46: 1141–1157 Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC (1986) Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol Pharmacol 30:427–436 Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK (1999) Alpha4 but not alpha3 and alpha7 nicotinic acetyl- choline receptor subunits are lost from the temporal cortex in Alzheimer’s disease. J Neurochem 73:1635–1640 Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK, Court JA (2003) Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 54:1222–1233 Martin-Ruiz CM, Lee M, Perry RH, Baumann M, Court JA, Perry EK (2004) Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res 123:81–90 Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM, Rossi F, Champtiaux N, Zoli M, Changeux JP (2003) Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 17:1329–1337 Marubio LM, Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove dA, Huchet M, Damaj MI, Changeux JP (1999) Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398:805–810 Marutle A, Warpman U, Bogdanovic N, Lannfelt L, Nordberg A (1999) Neuronal nicotinic recep- tor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. J Neurochem 72:1161–1169 Marutle A, Zhang X, Court J, Piggott M, Johnson M, Perry R, Perry E, Nordberg A (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22:115–126 McClure-Begley TD, King NM, Collins AC, Stitzel JA, Wehner JM, Butt CM (2009) Acetylcholine-stimulated [3H]GABA release from mouse brain synaptosomes is modulated by alpha4beta2 and alpha4alpha5beta2 nicotinic receptor subtypes. Mol Pharmacol 75:918–926 McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid PZ, Parker KW, Sanberg PR (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette’s disorder. Am J Psychiatry 148:793–794 McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB (1992) The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette’s disorder. Biol Psychiatry 31:832–840 McLellan A, Phillips HA, Rittey C, Kirkpatrick M, Mulley JC, Goudie D, Stephenson JB, Tolmie J, Scheffer IE, Berkovic SF, Zuberi SM (2003) Phenotypic comparison of two Scottish families with mutations in different genes causing autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia 44:613–617 Morley BJ, Kemp GE, Salvaterra P (1979) Alpha-Bungarotoxin binding sites in the CNS. Life Sci 24:859–872 Moser N, Mechawar N, Jones I, Gochberg-Sarver A, Orr-Urtreger A, Plomann M, Salas R, Molles B, Marubio L, Roth U, Maskos U, Winzer-Serhan U, Bourgeois JP, Le Sourd AM, De Biasi M, Schroder H, Lindstrom J, Maelicke A, Changeux JP, Wevers A (2007) Evaluating the suitabil- ity of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures. J Neurochem 102:479–492 Nicotinic Receptors in Brain Diseases 779 Moulard B, Picard F, Le Hellard S, Agulhon C, Weiland S, Favre I, Bertrand S, Malafosse A, Bertrand D (2001) Ion channel variation causes epilepsies. Brain Res Brain Res Rev 36: 275–284 Mousavi M, Bednar I, Nordberg A (2004) Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or over-expressing human acetylcholinestrase. Int J Dev Neurosci 22:545–549 Mousavi M, Hellstrom-Lindahl E, Guan ZZ, Shan KR, Ravid R, Nordberg A (2003) Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer’s disease. Neuroscience 122:515–520 Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363:2063–2072 Mulle C, Choquet D, Korn H, Changeux JP (1992) Calcium influx through nicotinic receptor in rat central neurons: its relevance to cellular regulation. Neuron 8:135–143 Nagele RG, D’Andrea MR, Anderson WJ, Wang HY (2002) Intracellular accumulation of beta- amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 110:199–211 NINDS (2008) Tourette syndrome fact sheet. http://www.ninds.nih.gov/disorders/tourette/detail_ tourette.htm Nordberg A, Adem A, Hardy J, Winblad B (1988) Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. Neurosci Lett 86:317–321 Nordberg A, Hellstrom-Lindahl E, Lee M, Johnson M, Mousavi M, Hall R, Perry E, Bednar I, Court J (2002) Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer’s disease (APPsw). J Neurochem 81:655–658 Nordberg A, Lundqvist H, Hartvig P, Lilja A, Langstrom B (1995) Kinetic analysis of regional (S)(–)11C-nicotine binding in normal and Alzheimer brains – in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 9:21–27 Nordberg A, Winblad B (1986) Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 72:115–119 Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of- concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638 Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, Dani JA, Patrick JW, Beaudet AL (1997) Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 17: 9165–9171 Orth M, Amann B, Robertson MM, Rothwell JC (2005) Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain 128:1292–1300 Oswald RE, Freeman JA (1981) Alpha-bungarotoxin binding and central nervous system nicotinic acetylcholine receptors. Neuroscience 6:1–14 O’Neill HC, Rieger K, Kem WR, Stevens KE (2003) DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl) 169:332–339 Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ (1999) Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 289:1545–1552 Perry EK, Lee ML, Martin-Ruiz CM, Court JA, Volsen SG, Merrit J, Folly E, Iversen PE, Bauman ML, Perry RH, Wenk GL (2001) Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 158:1058–1066 Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, Haroutunian V, Buxbaum JD, Nasland J, Davis K, Gotti C, Clementi F, Tzartos S, Cohen O, Soreq H, Jaros E, Perry R, Ballard C, McKeith I, Court J (2000) Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 393:215–222 Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH (1995) Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience 64:385–395 780 J.A. Stitzel Phillips HA, Favre I, Kirkpatrick M, Zuberi SM, Goudie D, Heron SE, Scheffer IE, Sutherland GR, Berkovic SF, Bertrand D, Mulley JC (2001) CHRNB2 is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy. Am J Hum Genet 68:225–231 Phillips HA, Marini C, Scheffer IE, Sutherland GR, Mulley JC, Berkovic SF (2000) A de novo mutation in sporadic nocturnal frontal lobe epilepsy. Ann Neurol 48: 264–267 Picard F, Bertrand S, Steinlein OK, Bertrand D (1999) Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia 40:1198–1209 Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, LeNovere N, Vincent P, Pich EM, Brulet P, Changeux JP (1995) Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374:65–67 Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, Ruppert A, Lodrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas DA, Silverman EK, Goldstein DB (2009) A genome-wide association study in chronic obstruc- tive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 5:e1000421 Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, Perry RH, Perry EK, Wyper D (2004) Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a- 85380. Neuropsychopharmacology 29:108–116 Poirier MF, Canceil O, Bayle F, Millet B, Bourdel MC, Moatti C, Olie JP, Attar-Levy D (2002) Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 26:529–537 Portugal GS, Gould TJ (2008) Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res 193:1–16 Quick MW, Lester RA (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53: 457–478 Quik M, Bordia T, Forno L, McIntosh JM (2004) Loss of alpha-conotoxinMII- and A85380- sensitive nicotinic receptors in Parkinson’s disease striatum. J Neurochem 88:668–679 Quik M, O’Leary K, Tanner CM (2008) Nicotine and Parkinson’s disease: implications for therapy. Mov Disord 23:1641–1652 Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, Grady SR (2003) Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 63:1169–1179 Quik M, Vailati S, Bordia T, Kulak JM, Fan H, McIntosh JM, Clementi F, Gotti C (2005) Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine or L-DOPA. Mol Pharmacol 67:32–41 Ragozzino D, Barabino B, Fucile S, Eusebi F (1998) Ca2+ permeability of mouse and chick nico- tinic acetylcholine receptors expressed in transiently transfected human cells. J Physiol 507(Pt 3):749–757 Ray MA, Graham AJ, Lee M, Perry RH, Court JA, Perry EK (2005) Neuronal nicotinic acetyl- choline receptor subunits in autism: an immunohistochemical investigation in the thalamus. Neurobiol Dis 19:366–377 Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P (1991) A postmortem study of brain nicotinic receptors in Parkinson’s and Alzheimer’s disease. Brain Res 547:167–170 Romano C, Goldstein A (1980) Stereospecific nicotine receptors on rat brain membranes. Science 210:647–650 Sabri O, Kendziorra K, Wolf H, Gertz HJ, Brust P (2008) Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 35(Suppl 1):S30–S45 Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP (2005) Effects of cigarette smoking on spatial working memory and attentional Nicotinic Receptors in Brain Diseases 781 deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 62:649–659 Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau O, Swan GE, Goate AM, Rutter J, Bertelsen S, Fox L, Fugman D, Martin NG, Montgomery GW, Wang JC, Ballinger DG, Rice JP, Bierut LJ (2007) Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16:36–49 Saccone NL, Saccone SF, Hinrichs AL, Stitzel JA, Duan W, Pergadia ML, Agrawal A, Breslau N, Grucza RA, Hatsukami D, Johnson EO, Madden PA, Swan GE, Wang JC, Goate AM, Rice JP, Bierut LJ (2009) Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet B Neuropsychiatr Genet 150B(4):453–466 Saenz A, Galan J, Caloustian C, Lorenzo F, Marquez C, Rodriguez N, Jimenez MD, Poza JJ, Cobo AM, Grid D, Prud’homme JF, Lopez dM (1999) Autosomal dominant nocturnal frontal lobe epilepsy in a Spanish family with a Ser252Phe mutation in the CHRNA4 gene. Arch Neurol 56:1004–1009 Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nico- tinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65: 1526–1535 Sanberg PR, Fogelson HM, Manderscheid PZ, Parker KW, Norman AB, McConville BJ (1988) Nicotine gum and haloperidol in Tourette’s syndrome. Lancet 1:592 Sanberg PR, McConville BJ, Fogelson HM, Manderscheid PZ, Parker KW, Blythe MM, Klykylo WM, Norman AB (1989) Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother 43:19–23 Scheffer IE, Bhatia KP, Lopes-Cendes I, Fish DR, Marsden CD, Andermann E, Andermann F, Desbiens R, Keene D, Cendes F, (1995) Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 118(Pt 1):61–73 Schlaepfer IR, Hoft NR, Collins AC, Corley RP, Hewitt JK, Hopfer CJ, Lessem JM, McQueen MB, Rhee SH, Ehringer MA (2008) The CHRNA5/A3/B4 gene cluster variability as an impor- tant determinant of early alcohol and tobacco initiation in young adults. Biol Psychiatry 63: 1039–1046 Schwartz RD, Kellar KJ (1983) Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 220:214–216 Schwartz RD, McGee R Jr, Kellar KJ (1982) Nicotinic cholinergic receptors labeled by [3H]acetylcholine in rat brain. Mol Pharmacol 22:56–62 Schwarz J, Schwarz SC, Dorigo O, Stutzer A, Wegner F, Labarca C, Deshpande P, Gil JS, Berk AJ, Lester HA (2006) Enhanced expression of hypersensitive alpha4 ∗ nAChR in adult mice increases the loss of midbrain dopaminergic neurons. FASEB J 20:935–946 Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13:596–604 Seidl R, Tiefenthaler M, Hauser E, Lubec G (2000) Effects of transdermal nicotine on cognitive performance in Down’s syndrome. Lancet 356:1409–1410 Sershen H, Reith ME, Lajtha A, Gennaro J Jr (1981) Noncholinergic, saturable binding of (+/-)- [3H]nicotine to mouse brain. J Recept Res 2:1–15 Sherva R, Wilhelmsen K, Pomerleau CS, Chasse SA, Rice JP, Snedecor SM, Bierut LJ, Neuman RJ, Pomerleau OF (2008) Association of a single nucleotide polymorphism in neuronal acetyl- choline receptor subunit alpha 5 (CHRNA5) with smoking status and with ‘pleasurable buzz’ during early experimentation with smoking. Addiction 103:1544–1552 Shiraishi K, Kohno T, Kunitoh H, Watanabe S, Goto K, Nishiwaki Y, Shimada Y, Hirose H, Saito I, Kuchiba A, Yamamoto S, Yokota J (2009) Contribution of nicotine acetylcholine recep- tor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis 30:65–70 782 J.A. Stitzel Silver AA, Shytle RD, Philipp MK, Sanberg PR (1996) Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 35:1631–1636 Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR (2001) Transdermal nicotine and haloperidol in Tourette’s disorder: a double-blind placebo-controlled study. J Clin Psychiatry 62:707–714 Simosky JK, Stevens KE, Freedman R (2002) Nicotinic agonists and psychosis. Curr Drug Targets CNS Neurol Disord 1:149–162 Simosky JK, Stevens KE, Kem WR, Freedman R (2001) Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry 50:493–500 Soderman A, Thomsen MS, Hansen HH, Nielsen EO, Jensen MS, West MJ, Mikkelsen JD (2008) The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42. Brain Res 1227:240–247 Song P, Spindel ER (2008) Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci 106:180–185 Spitz MR, Amos CI, Dong Q, Lin J, Wu X (2008) The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst 100:1552–1556 Steinlein OK, Bertrand D (2008) Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases. Biochem Pharmacol 76:1175–1183 Steinlein OK, Magnusson A, Stoodt J, Bertrand S, Weiland S, Berkovic SF, Nakken KO, Propping P, Bertrand D (1997) An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum Mol Genet 6:943–947 Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF (1995) A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 11:201–203 Steinlein OK, Stoodt J, Mulley J, Berkovic S, Scheffer IE, Brodtkorb E (2000) Independent occur- rence of the CHRNA4 Ser248Phe mutation in a Norwegian family with nocturnal frontal lobe epilepsy. Epilepsia 41:529–535 Stevens KE, Adams CE, Mellott TJ, Robbins E, Kisley MA (2008a) Perinatal choline deficiency produces abnormal sensory inhibition in Sprague-Dawley rats. Brain Res 1237:84–90 Stevens KE, Adams CE, Yonchek J, Hickel C, Danielson J, Kisley MA (2008b) Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline. Psychopharmacology (Berl) 198:413–420 Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Henrichs AL, Thun MJ, Goate A, Calle EE (2008) Nicotinic Receptor Gene Variants Influence Susceptibility to Heavy Smoking. Cancer Epidemiol Biomarkers Prev 17:3517–3525 Stevens KE, Kem WR, Mahnir VM, Freedman R (1998) Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 136: 320–327 Stevens KE, Stitzel JA, Jimenez M, Collins AC 2001 Transferring the alpha7 nicotinic receptor between different mouse backgrounds alters auditory gating. Society for Neuroscience Annual Meeting Abstract viewer/Itinerary planner, San Diego, CA, Program Number: 145.4. Stevens KE, Wear KD (1997) Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav 57:869–874 Stitzel JA (2008) Naturally occurring genetic variability in the nicotinic acetylcholine receptor alpha4 and alpha7 subunit genes and phenotypic diversity in humans and mice. Front Biosci 13:477–491 Stitzel JA, Farnham DA, Collins AC (1996) Linkage of strain-specific nicotinic receptor alpha 7 subunit restriction fragment length polymorphisms with levels of alpha-bungarotoxin binding in brain. Brain Res Mol Brain Res 43:30–40 Nicotinic Receptors in Brain Diseases 783 Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, Perry E (2003) Alzheimer’s disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41:207–211 Terzano S, Court JA, Fornasari D, Griffiths M, Spurden DP, Lloyd S, Perry RH, Perry EK, Clementi F (1998) Expression of the alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer’s disease. Brain Res Mol Brain Res 63:72–78 Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsater A, Flex A, Aben KK, de Vegt F, Mulders PF, Isla D, Vidal MJ, Asin L, Saez B, Murillo L, Blondal T, Kolbeinsson H, Stefansson JG, Hansdottir I, Runarsdottir V, Pola R, Lindblad B, van Rij AM, Dieplinger B, Haltmayer M, Mayordomo JI, Kiemeney LA, Matthiasson SE, Oskarsson H, Tyrfingsson T, Gudbjartsson DF, Gulcher JR, Jonsson S, Thorsteinsdottir U, Kong A, Stefansson K (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452:638–642 Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM (2005) Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend 80:259–265 Tozaki H, Matsumoto A, Kanno T, Nagai K, Nagata T, Yamamoto S, Nishizaki T (2002) The inhibitory and facilitatory actions of amyloid-beta peptides on nicotinic ACh receptors and AMPA receptors. Biochem Biophys Res Commun 294:42–45 Venables PH (1964) Input dysfunction in schizophrenia. Prog Exp Pers Res 72:1–47 Venables PH (1992) Hippocampal function and schizophrenia. Experimental psychological evi- dence. Ann N Y Acad Sci 658:111–127 Volkow N, Rutter J, Pollock JD, Shurtleff D, Baler R (2008) One SNP linked to two diseases- addiction and cancer: a double whammy? Nicotine addiction and lung cancer susceptibility. Mol Psychiatry 13:990–992 Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP, Duan W, Fox L, Grucza RA, Kern J, Mayo K, Reyes O, Rice J, Saccone SF, Spiegel N, Steinbach JH, Stitzel JA, Anderson MW, You M, Stevens VL, Bierut LJ, Goate AM (2009) Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet 18(16):3125–3135 Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde JP, Fox L, Goldstein E, Reyes O, Saccone N, Saccone S, Xuei X, Bucholz K, Kuperman S, Nurnberger J Jr, Rice JP, Schuckit M, Tischfield J, Hesselbrock V, Porjesz B, Edenberg HJ, Bierut LJ, Goate AM (2008) Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry 14(5):501–510 Wang HY, Lee DH, D’Andrea MR, Peterson PA, Shank RP, Reitz AB (2000a) beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem 275:5626–5632 Wang HY, Lee DH, Davis CB, Shank RP (2000b) Amyloid peptide Abeta(1-42) binds selec- tively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75: 1155–1161 Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N, Singh NA, Baird L, Coon H, McMahon WM, Piper ME, Fiore MC, Scholand MB, Connett JE, Kanner RE, Gahring LC, Rogers SW, Hoidal JR, Leppert MF (2008) A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet 4:e1000125 Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, Pereira EF, Eisenberg H, Giacobini E, de Vos RA, Steur EN, Maelicke A, Albuquerque EX, Schroder H (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer’s disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11:2551–2565 784 J.A. Stitzel Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, Kellar KJ (1986) Nicotinic acetylcholine binding sites in Alzheimer’s disease. Brain Res 371:146–151 Whitehouse PJ, Martino AM, Wagster MV, Price DL, Mayeux R, Atack JR, Kellar KJ (1988) Reductions in [3H]nicotinic acetylcholine binding in Alzheimer’s disease and Parkinson’s disease: an autoradiographic study. Neurology 38:720–723 Whiting PJ, Schoepfer R, Conroy WG, Gore MJ, Keyser KT, Shimasaki S, Esch F, Lindstrom JM (1991) Expression of nicotinic acetylcholine receptor subtypes in brain and retina. Brain Res Mol Brain Res 10:61–70 Wildeboer KM, Stevens KE (2008) Stimulation of the alpha4beta2 nicotinic receptor by 5-I A- 85380 improves auditory gating in DBA/2 mice. Brain Res 1224:29–36 Williams JM, Ziedonis D (2004) Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 29:1067–1083 Willoughby JO, Pope KJ, Eaton V (2003) Nicotine as an antiepileptic agent in ADNFLE: an N-of- one study. Epilepsia 44:1238–1240 Wonnacott S (1990) The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 11:216–219 Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA (2003) Differential desensitization and dis- tribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci 23:3176–3185 Wu J, Kuo YP, George AA, Xu L, Hu J, Lukas RJ (2004) beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem 279:37842–37851 Yates CM, Simpson J, Maloney AF, Gordon A, Reid AH (1980) Alzheimer-like cholinergic deficiency in Down syndrome. Lancet 2:979 Young RP, Hopkins RJ, Hay BA, Epton MJ, Black PN, Gamble GD (2008) Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J 32: 1158–1164 Zamani MR, Allen YS, Owen GP, Gray JA (1997) Nicotine modulates the neurotoxic effect of beta-amyloid protein(25–35) in hippocampal cultures. Neuroreport 8:513–517 Zhang J, Liu Q, Chen Q, Liu NQ, Li FL, Lu ZB, Qin C, Zhu H, Huang YY, He W, Zhao BL (2006) Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis. FASEB J 20:1212–1214 Zhu PJ, Chiappinelli VA (1999) Nicotine modulates evoked GABAergic transmission in the brain. J Neurophysiol 82:3041–3045 Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C (2002) Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 22:8785–8789 Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP (1999) Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J 18:1235–1244 . nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21: 1452–1463 Nicotinic Receptors in Brain Diseases 777 Kulak JM, Musachio JL, McIntosh JM, Quik M (2002) Declines. 226:817–825 778 J.A. Stitzel Marks MJ, Collins AC (1982) Characterization of nicotine binding in mouse brain and compar- ison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate. Mol Pharmacol. fragment length polymorphisms with levels of alpha-bungarotoxin binding in brain. Brain Res Mol Brain Res 43:30–40 Nicotinic Receptors in Brain Diseases 783 Teaktong T, Graham A, Court J, Perry R, Jaros